Gsk (GLAXF) Common Equity (2009 - 2026)

Gsk's Common Equity history runs 18 years deep, the most recent figure standing at $23.5 billion for Q1 2026.

• In Q1 2026, Common Equity rose 36.58% year-over-year to $23.5 billion; the TTM figure through Mar 2026 stood at $23.5 billion (up 36.58% YoY), while the FY2025 annual figure was $21.0 billion, up 20.39% from the prior year.
• Common Equity was $23.5 billion for Q1 2026 at Gsk, up from $21.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $36.0 billion in Q1 2022 to a low of $10.3 billion in Q3 2022.
• Historically, Common Equity has averaged $18.8 billion across 5 years, with a median of $17.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity sank 65.74% in 2022, then surged 55.61% in 2023.
• A 5-year view of Common Equity shows it stood at $12.4 billion in 2022, then jumped by 33.26% to $16.6 billion in 2023, then increased by 5.92% to $17.5 billion in 2024, then advanced by 20.96% to $21.2 billion in 2025, then increased by 10.67% to $23.5 billion in 2026.
• The last three Common Equity figures came in at $23.5 billion (Q1 2026), $21.2 billion (Q4 2025), and $21.3 billion (Q3 2025), per Business Quant data.